In today’s briefing:
- SciClone Pharma (6600 HK): Inexpensive Ahead Of New Therapies Rolling Out
- Smartkarma Corporate Webinar | New Horizon Health: A Case of Successful Commercialization
- Liquid Universe of European Ordinary and Preferred Shares: February ‘23 Report
- Genscript Biotech (1548.HK) – Inadequate Cognition Will Lead to Bad Investment Decisions
- Newron Pharmaceuticals – Evenamide efficacy still going strong after 52 weeks
- OSE Immunotherapeutics – FDA support received for Tedopi Phase III trial
SciClone Pharma (6600 HK): Inexpensive Ahead Of New Therapies Rolling Out
- Shareholders have given SciClone Pharmaceuticals (6600 HK)‘s buyback the go-ahead which will result in the major shareholder holding (upward of) 31.63%, and the freedom to creep.
- As such, a concentrated shareholder register, primarily comprising entities that privatised SciClone in 2017, gets even more concentrated.
- Trading inexpensively ahead of the launch of a new (and approved) drug, SciClone is worth a second look.
Smartkarma Corporate Webinar | New Horizon Health: A Case of Successful Commercialization
For our next Corporate Webinar we are glad to welcome New Horizon Health’s CFO, Yu Gao.
In the upcoming webinar, Mr Gao will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Ke Yan. The Corporate Webinar will include a live Q&A session.
The Corporate Webinar will be hosted on Tuesday, 21 February 2023, 17:00 SGT.
About New Horizon Health
New Horizon Health (6606 HK) is a biotech focusing on the research, development and commercialization of molecular diagnostics for cancer screening in China and globally. New Horizon Health currently has three NMPA approved cancer screening tests: ColoClear: the only colorectal cancer screening test approved by NMPA (Class III medical device) for high-risk colorectal cancer population in China; Pupu Tube: the only self-conducted FIT test approved by NMPA (Class II medical device) for average-risk colorectal cancer population in China. It also obtained CE Mark in 2018; and UU Tube: the only self-conducted H. Pylori diagnostic test approved by NMPA (Class III medical device) in China. It also obtained CE Mark in 2022. The company also has pipeline tests, as well as many other undisclosed cancer screening tests under research development.
Liquid Universe of European Ordinary and Preferred Shares: February ‘23 Report
- Since mid-January, spreads have generally tightened across our liquid universe (8 have widened, 10 tightened, 1 at same level).
- Trade recommendations long ords / short prefs: Fuchs Petrolub, Henkel, Handelsbanken, SSAB Svenska Stal.
- Trade recommendations long prefs / short ords: Carlsberg, Sixt, VW, Danieli, MFE-Media for Europe, Grifols, Atlas Copco, Ericsson.
Genscript Biotech (1548.HK) – Inadequate Cognition Will Lead to Bad Investment Decisions
- Genscript doesn’t equal to CGT CXO or cell therapy company,although these two businesses have attracted a lot of attention. It’s inappropriate to look at Genscript only from these two perspectives.
- Genscript’s strength and core basic business is gene synthesis,which would remain promising growth. We’re also optimistic about Bestzyme. The chaos in CGT field won’t have a material impact on Genscript.
- Investing a company/stock is essentially investing the people. Although Genscript has its core competence, our concern about this company lies in the management. Short-term trading is more appropriate for Genscript.
Newron Pharmaceuticals – Evenamide efficacy still going strong after 52 weeks
Newron Pharmaceuticals has announced positive interim results from the first 100 randomised patients completing one year of treatment (77 out of 100) in the Phase II 014/015 clinical trial (international, open label, rater-blinded study), in which evenamide is an add-on therapy to antipsychotics in moderate to severe treatment-resistant schizophrenia (TRS). The data are consistent with a gradual and sustained pattern of improvement in key efficacy measures compared with results after six weeks and six months of treatment, with the proportion of patients achieving meaningful improvements increasing over time. We view these updated results as particularly encouraging for evenamide as an effective treatment for TRS, and continued justification of Newron’s strategy to expand into this schizophrenia patient population.
OSE Immunotherapeutics – FDA support received for Tedopi Phase III trial
OSE has announced that it has received positive recommendations from its ‘type C’ meeting with the FDA for the planned confirmatory Phase III trial design for Tedopi (neoepitope cancer vaccine), as a second-line treatment in advanced or metastatic non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure. This follows similar advice from the European Medicines Agency (EMA). The company will now undertake the pivotal trial as monotherapy (against standard of care) under this protocol, for patients with HLA-A2+ tumours (c 45% of total population). As a reminder, OSE reported positive data from the previous Phase III ATALANTE-1 trial as second/third-line treatment, although enrolment had to be terminated prematurely due to the COVID-19 pandemic.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars